Confirmatory study of TRK-820 Soft Capsules-Intractable Pruritus in Patients with Chronic Liver Disease-

Trial Profile

Confirmatory study of TRK-820 Soft Capsules-Intractable Pruritus in Patients with Chronic Liver Disease-

Completed
Phase of Trial: Phase III

Latest Information Update: 01 Sep 2017

At a glance

  • Drugs Nalfurafine (Primary)
  • Indications Pruritus
  • Focus Therapeutic Use
  • Sponsors Toray
  • Most Recent Events

    • 01 Sep 2017 Primary endpoint (STEP I, The difference in changes in VAS (week 4 [LOCF]) between the placebo and 5 microgram groups) has been met, according to result published in the Hepatology Research.
    • 01 Sep 2017 Primary endpoint (STEP II, The difference in changes in VAS (week 4 [LOCF]) between the placebo and 2.5 microgram groups) has been met, according to result published in the Hepatology Research.
    • 01 Sep 2017 Results assessing the efficacy and safety of the nalfurafine hydrochloride in the treatment of refractory pruritus in patients with chronic liver disease, were published in the Hepatology Research.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top